Background: Pulmonary artery hypertension (PAH) is a chronic and progressive disease. Although current therapy has improved the disease prognosis, PAH has a poor survival rate. The key feature leading to disease progression and death is right ventricular (RV) failure. Methods and results: We assessed the role of trimetazidine, a fatty acid beta-oxidation (FAO) inhibitor, in right ventricular function, remodeling, and functional class in PAH patients, with a placebo-controlled double-blind, case-crossover trial. Twenty-seven PAH subjects were enrolled, randomized, and assigned to trimetazidine or placebo for three months and then reallocated to the other study arm. The primary endpoint was RV morphology and function change after three months of treatment. Secondary endpoints were the change in exercise capacity assessed by a 6 min walk test after three months of treatment and the change in pro-BNP and Galectin-3 plasma levels after three months. Trimetazidine use was safe and well-tolerated. After three months of treatment, patients in the trimetazidine group showed a small but significant reduction of RV diastolic area, and a substantial increase in the 6 min walk distance (418 vs. 438 mt, p = 0.023), without significant changes in biomarkers. Conclusions: A short course of trimetazidine is safe and well-tolerated on PAH patients, and it is associated with significant increases in the 6MWT and minor but significant improvement in RV remodeling. The therapeutic potential of this drug should be evaluated in larger clinical trials.
Periodontitis is a chronic inflammatory disease characterized by the progressive and irreversible destruction of the periodontium. Its aetiopathogenesis lies in the constant challenge of the dysbiotic biofilm, which triggers a deregulated immune response responsible for the disease phenotype. Although the molecular mechanisms underlying periodontitis have been extensively studied, the regulatory mechanisms at the transcriptional level remain unclear. To generate transcriptomic data, we performed RNA shotgun sequencing of the oral mucosa of periodontitis-affected mice. Since genes are not expressed in isolation during pathological processes, we disclose here the complete repertoire of differentially expressed genes (DEG) and co-expressed modules to build Gene Regulatory Networks (GRNs) and identify the Master Transcriptional Regulators of periodontitis. The transcriptional changes revealed 366 protein-coding genes and 42 non-coding genes differentially expressed and enriched in the immune response. Furthermore, we found 13 co-expression modules with different representation degrees and gene expression levels. Our GRN comprises genes from 12 gene clusters, 166 nodes, of which 33 encode Transcription Factors, and 201 connections. Finally, using these strategies, 26 master regulators of periodontitis were identified. In conclusion, combining the transcriptomic analyses with the regulatory network construction represents a powerful and efficient strategy for identifying potential periodontitis-therapeutic targets.
Impaired wound healing in aged and diabetic wounds involves complex cellular dysregulation that hinders tissue repair. Using single‐cell RNA sequencing (scRNA‐seq) and validation techniques, we investigated impaired wound healing to identify whether there were significant changes linked to each condition. Comparative mucosal wound analysis revealed distinct differences between diabetic and normoglycemic (NG)‐aged mice, which had an impact on connective tissue formation and epithelial closure. Wounds in NG‐aged mice exhibited prolonged granulation tissue and upregulation of genes linked to chemotaxis, cell migration, neutrophil degranulation, and antimicrobial defense pathways compared to the diabetic wounds. In comparison to healing in young animals, wounds in NG‐aged mice had a shift in fibroblast subtypes with fewer matrix‐producing myofibroblasts and increased inflammatory fibroblasts. Furthermore, wounds in NG‐aged mice versus wounds in diabetic mice had an upregulation of lytic enzymes, with striking differences in cathepsin‐expressing fibroblasts. Since diabetic wounds healed more slowly than wounds in NG‐aged mice, the results suggest that the upregulation of lytic enzymes that characterized diabetic wounds is particularly damaging to healing. In addition to the transcriptional differences, pseudotime analysis revealed that fibroblasts in wounds from diabetic mice progressed towards a protease‐enriched state, while those in aged mice shifted towards an inflammatory phenotype. This is the first study to directly compare aged and diabetic healing at the single‐cell level and provides distinct molecular mechanisms that may allow more precise therapeutic targets to improve healing in aged and diabetic wounds.